Symptom clusters as predictors of late response to antidepressant treatment

Journal of Clinical Psychiatry

Volumn 66, Issue 8, 2005, Pages 1064-1070

  Trivedi, Madhukar H ^a   Morris, David W ^a   Grannemann, Bruce D ^a   Mahadi, Susan ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; NEFAZODONE;

ADULT; ANXIETY; APPETITE; ARTICLE; BODY WEIGHT; DEPRESSION; FEMALE; HAMILTON SCALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOOD; PRIORITY JOURNAL; SLEEP; SYMPTOMATOLOGY; TREATMENT OUTCOME;

EID: 23944472352     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v66n0816     Document Type: Article

References (56)

1. Bielski RJ, Friedel RO. Prediction of tricyclic antidepressant response: a critical review. Arch Gen Psychiatry 1976;33:1479-1489
2. Greenhouse JB, Kupfer DJ, Frank E, et al. Analysis of time to stabilization in the treatment of depression biological and clinical correlates. J Affect Disord 1987;13:259-266
3. Katz MM, Koslow SH, Maas JW, et al. The timing, specificity and clinical prediction of tricyclic drug effects in depression. Psychol Med 1987;17:297-309
4. Hooley JM, Teasdale JD. Predictors of relapse in unipolar depressives: expressed emotion, marital distress, and perceived criticism. J Abnorm Psychol 1989;98:229-235
5. Joyce PR, Paykel ES. Predictors of drug response in depression. Arch Gen Psychiatry 1989;46:89-99
6. Kocsis JH, Mason BJ, Frances AJ, et al. Prediction of response of chronic depression to imipramine. J Affect Disord 1989;17:255-260
7. Kocsis JH. New issues in the prediction of antidepressant response. Psychopharmacol Bull 1990;26:49-53
8. Brugha TS, Bebbington PE, Stretch DD, et al. Predicting the short-term outcome of first episodes and recurrences of clinical depression: a prospective study of life events, difficulties, and social support networks. J Clin Psychiatry 1997;58:298-306
9. Reimherr FW, Chouinard G, Cohn CK. Antidepressant efficacy of sertraline: a double-blind, placebo- and amitriptyline-controlled, multicenter comparison study in outpatients with major depression. J Clin Psychiatry 1990;51(12 suppl B):18-27
10. Vallejo J, Gasto C, Catalan R, et al. Predictors of antidepressant treatment outcome in melancholia: psychosocial, clinical and biological indicators. J Affect Disord 1991;21:151-162
11. Keller MB, Lavori PW, Mueller TL, et al. Time to recovery, chronicity, and levels of psychopathology in major depression: a 5-year prospective follow-up of 431 subjects. Arch Gen Psychiatry 1992;49:809-816
12. Goodwin FK. Predictors of antidepressant response. Bull Menninger Clin 1993;57:146-160
13. Friedman RA, Parides M, Baff R, et al. Predictors of response to desipramine in dysthymia. J Clin Psychopharmacol 1995;15:280-283
14. Cohn CK, Robinson DS, Roberts DL, et al. Responders to antidepressant drug treatment: a study comparing nefazodone, imipramine, and placebo in patients with major depression. J Clin Psychiatry 1996;57(suppl 2):15-18
15. Aliapoulous J, Zisook S. Tricyclic antidepressants medications. In: Goodnick PJ, ed. Predictors of Treatment Response in Mood Disorders. Washington, DC: American Psychiatric Press. Inc; 1996:1-36
16. Nierenberg AA. Predictors of response to antidepressants general principles and clinical implications. Psychiatr Clin North Am 2003;26:345-352
17. Fava M, Uebelacker LA, Alpert JE, et al. Major depressive subtypes and treatment response. Biol Psychiatry 1997;42:568-576
18. Lebowitz MR, Quitkin FM. Stewart JW, et al. Antidepressant specificity in atypical depression. Arch Gen Psychiatry 1988;45:129-137
19. Trivedi MH, Rush AJ, Crismon ML, et al. The Texas Medication Algorithm Project (TMAP): clinical results for patients with major depressive disorder. Arch Gen Psychiatry 2004;61:669-680
20. Paykel ES, Parker RR, Penrose RJ, et al. Depressive classification and prediction of response to phenelzine. Br J Psychiatry 1979;134:572-581
21. Croughan JL, Secunda SK, Katz MM, et al. Sociodemographic and prior clinical course characteristics associated with treatment response in depressed patients. J Psychiatr Res 1988;22:227-237
22. Khan A, Dager SR, Cohen S, et al. Chronicity of depressive episode in relation to antidepressant-placebo response. Neuropsychopharmacology 1991;4:125-130
23. Sotsky SM, Glass DR, Shea MT, et al. Patient predictors of response to psychotherapy and pharmacotherapy: findings in the NIMH treatment of depression collaborative research program. Am J Psychiatry 1991;148:997-1008
24. Pande AC, Sayler ME. Severity of depression and response to fluoxetine. Int Clin Psychopharmacol 1993;8:243-245
25. Hoencamp E, Haffmans PM, Duivenvoorden H, et al. Predictors of (non-) response in depressed outpatients treated with three-phase sequential medication strategy. J Affect Disord 1994;31:235-246
26. Ackerman DL, Greenland S, Bystritsky A, et al. Characteristics of fluoxetine versus placebo responders in a randomized trial of geriatric depression. Psychopharmacol Bull 1997;33:707-714
27. Esposito K, Goodnick P. Predictors of response in depression. Psychiatr Clin North Am 2003;26:353-365
28. Quitkin FM, Rabkin JG, Ross D, et al. Identification of true drug response to antidepressants: use of pattern analysis. Arch Gen Psychiatry 1984;41:782-786
29. Quitkin FM, McGrath PJ, Stewart JW, et al. Chronological milestones to guide drug change: when should clinicians switch antidepressants? Arch Gen Psychiatry 1996;53:785-792
30. Quitkin FM, Rabkin JD, Markowitz JM, et al. Use of pattern analysis to identify true drug response: a replication. Arch Gen Psychiatry 1987;44:259-264
31. Quitkin FM, McGrath PJ, Rabkin JG, et al. Different types of placebo response in patients receiving antidepressants. Am J Psychiatry 1991;148:197-203
32. Rothschild R, Quitkin FM. Review of the use of pattern analysis to differentiate true drug and placebo responses. Psychother Psychosom 1992;58:170-177
33. Stewart JW, Quitkin FM, McGrath PJ, et al. Use of pattern analysis to predict differential relapse of remitted patients with major depression during 1 year of treatment with fluoxetine or placebo. Arch Gen Psychiatry 1998;55:334-343
34. Quitkin FM, Rabkin JG, Ross D, et al. Duration of antidepressant drug treatment: what is an adequate trial? Arch Gen Psychiatry 1984;41:238-245
35. Donovan SJ, Quitkin FM, Stewart JW, et al. Duration of antidepressant trials: clinical and research implications. J Clin Psychopharmacol 1994;14:64-66
36. Nierenberg AA, Farabaugh AH, Alpert JE, et al. Timing of onset of antidepressant response with fluoxetine treatment. Am J Psychiatry 2000;157:1423-1428
37. Gelenberg AJ, Chesen CL. How fast are antidepressants? J Clin Psychiatry 2000;61:712-721
38. Quitkin FM, Petkova E, McGrath PJ, et al. When should a trial of fluoxetine for major depression be declared failed? Am J Psychiatry 2003;160:734-740
39. Trivedi MH, Morris DW, Pan J-Y, et al. Which moderator characteristics are associated with better prognosis for depression? Neuropsychiatric Disease and Treatment 2005;1:51-57
40. Rush AJ, Fava M, Wisniewski SR, et al. Sequenced Treatment Alternatives to Relieve Depression (STAR*D): rationale and design. Control Clin Trials 2004;25:118-141
41. Trivedi MH, Rush AJ, Crismon ML, et al. Treatment Guidelines and Algorithms. In: Dunner DL, Rosenbaum JF, eds. The Psychiatric Clinics of North America: Annual of Drug Therapy. Vol 7. Philadelphia, Pa: WB Saunders; 2000:1-22.
42. Trivedi MH, Baker SM. Clinical significance of monitoring early symptom change to predict outcomes. J Clin Psychiatry 2001;62:27-33
43. Entsuah R, Derivan A, Kikta D. Early onset of antidepressant action of venlafaxine: pattern analysis in intent-to-treat patients. Clin Ther 1998;20:517-526
44. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62
45. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967;6:278-296
46. Tollefson GD, Holman SL. How long to onset of antidepressant action: a meta-analysis of patients treated with fluoxetine or placebo. Int Clin Psychopharmacol 1994;9:245-250
47. O'Brien KP, Glaudin V. Factorial structure and factor reliability of the Hamilton Rating Scale for Depression. Acta Psychiatr Scand 1988;78:113-120
48. Riskind JH, Beck AT, Brown G, et al. Taking the measure of anxiety and depression: validity of the reconstructed Hamilton scales. J Nerv Ment Dis 1987;175:474-479
49. Fleck MP, Poirier-Littre MF, Guelfi JD, et al. Factorial structure of the 17-item Hamilton Depression Rating Scale. Acta Psychiatr Scand 1995;92:168-172
50. Guillion CM, Rush AJ. Toward a generalizable model of symptoms in major depressive disorder. Biol Psychiatry 1998;44:959-972
51. Mendels J, Kiev A, Fabre LF. Double-blind comparison of citalopram and placebo in depressed outpatients with melancholia. Depress Anxiety 1999;9:54-60
52. Trivedi MH, Rush AJ, Pan JY, et al. Which depressed patients respond to nefazodone and when? J Clin Psychiatry 2001;62:158-163
53. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Third Edition, Revised. Washington, DC: American Psychiatric Association; 1987
54. Treatment of Depression-Newer Pharmacotherapies. Evidence Report/ Technology Assessment, no. 7, March 1999. Agency for Health Care Policy and Research. Available at: http://www.ahrq.gov/clinic/epcsums/ deprsumm.htm. Accessibility verified June 14, 2005
55. Gibbons RD, Clark DC, Kupfer DJ. Exactly what does the Hamilton Depression Rating Scale measure? J Psychiatr Res 1993;27:259-273
56. Nunnally JC. Psychometric Theory. 2nd ed. New York, NY: McGraw-Hill; 1978